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Abstract First-trimester chorionic-villi-derived cells (FTCVs)
are the earliest fetal material that can be obtained for prenatal
diagnosis of fetal disorders such as Duchenne muscular dystro-
phy (DMD). DMD is a devastating X-linked disorder charac-
terized by the absence of dystrophin at the sarcolemma of
muscle fibers. Currently, a limited number of treatment options
are available for DMD, although cell therapy is a promising
treatment strategy for muscle degeneration in DMD patients.
A novel candidate source of cells for this approach is FTCVs
taken between the 9th and 11th weeks of gestation. FTCVs
might have a higher undifferentiated potential than any other
tissue-derived cells because they are the earliest fetal material.
We examined the expression of mesenchymal stem cell and
pluripotent stem cell markers in FTCVs, in addition to their
myogenicpotential.FTCVsexpressedmesenchymalstemcell
markers and Nanog and Sox2 transcription factors as pluripo-
tent stem cell markers. These cells efficiently differentiated
into myotubes after myogenic induction, at which point
Nanog and Sox2 were down-regulated, whereas MyoD, myo-
genin, desmin and dystrophin were up-regulated. To our
knowledge, this is the first demonstration that FTCVs can be
efficiently directed to differentiateinvitro into skeletalmuscle
cells that express dystrophin as the last stage marker of myo-
genic differentiation. The myogenic potential of FTCVs
reveals their promise for use in cell therapy for DMD, for





In the early 1980s, prenatal diagnosis by using chorionic
villus sampling (CVS) was introduced; this method has
advanced the diagnosis of fetal genetic disorders such as
Duchenne muscular dystrophy (DMD) in the first-trimester
of pregnancy. The numerous advances in prenatal diagnosis
and molecular genetic testing of DMD have permitted the
accurate and early diagnosis of carrier women.
During human development, the morula constitutes the
inner cell mass and the outer cell mass. The outer cell mass
forms the trophoblasts, which later contribute to the formation
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from the trophoblasts give rise to the chorionic villi (Sadler
2009). The first-trimester chorionic villi can be collected for
CVS. By the third trimester of pregnancy, the placenta consists
in two components: a fetal portion, which is derived from the
chorionicvillus,thesmoothchorion,thechorionicplateandthe
amnion and a maternal portion.
Of note, the first-trimester chorionic-villi-derived cells
(FTCVs) are the earliest fetal material that can be obtained
during pregnancy. Despite the presence of stem cells in the
FTCV population, only a few detailed reports have been
presented on the differentiation capability of fetal cells
obtained from CVS (Poloni et al. 2008; Spitalieri et al.
2009). Furthermore, third-trimester placental chorionic-villi-
derived cells (TTCVs) are either myogenic progenitors or
have myogenic potential (Kawamichi et al. 2010).
DMD is the most common and severe form of muscular
dystrophy. DMD is an X-linked recessive genetic disease that
affects 1 in 3,500 newborn male children and is caused by a
deficiency in dystrophin, which is associated with a large
oligomeric complex ofglycoproteins that linkthecytoskeleton
to the extracellular matrix (Ervasti and Campbell 1991). The
absence of dystrophin results in the destabilization of the
architecture of the extracellular membrane/sarcolemma cyto-
skeleton, making muscle fibers susceptible to contraction-
associated mechanical stress and degeneration.
Unfortunately, no curative therapy is available for DMD,
although a few novel treatments, including pharmacologic
agents and genetic alterations for replacing the missing dystro-
phin by exon skipping or viral gene delivery, are in clinical
trials (Kinali et al. 2009; Miyagoe-Suzuki and Takeda 2010).
Another attractive alternative for treating DMD is cell therapy
foreverygenemutationinpatients.Inparticular,myoblastsare
the first choice as cellular therapeutics for skeletal muscle,
because of their intrinsic myogenic commitment (Grounds et
al.2002).However,myoblastsrecoveredfrommusclebiopsies
areknowntobepoorlyexpandableinvitroandrapidlysenesce
(Cossu and Mavilio 2000). Therefore, an alternative source of
muscle progenitor cells is desirable. Accordingly, researchers
have become interested in a variety of other cells with
myogenic potential, including bone marrow stromal cells
(Saburina et al. 2004), blood-vessel-associated mesoangio-
blasts (Sampaolesi et al. 2006), umbilical cord blood cells
(Gang et al. 2004), adipose tissue cells (Di Rocco et al.
2006), endometrial and menstrual blood cells (Cui et al.
2007), placenta cells (Kawamichi et al. 2010) and induced
pluripotent stem cells from DMD (Kazuki et al. 2010).
In this study, we have identified a subpopulation of cells
that express various markers of mesenchymal stem cells
(MSCs) and pluripotent stem cells in the larger FTCV
population. Subsequently, we have found that directed dif-
ferentiation of the FTCVs into skeletal muscle cells in vitro
efficiently generates dystrophin-positive myotubes.
Materials and methods
Isolation of first-trimester chorionic villi and placental
tissues
First-trimester chorionic villi were excised from subjects un-
dergoing prenatal diagnosis between the 9th and 11th weeks
of gestation. Each biopsy was performed by using standard
procedures under continuous ultrasound guidance. The
human placentas were collected between the 37th and 41st
weeks of gestation (third trimester) during normal full-term
deliveries. For this study, the first-trimester chorionic villi
were obtained from 12 individuals and placentas were
obtained from five individuals. Of note, the cells from both
these sources are established as having the normal full-length
dystrophin gene without any mutations. Informed patientcon-
sent was obtained in all cases. Ethical approval for tissue
collection was granted by the Institutional Review Board of
Tokyo Women’s Medical University, Japan.
Tissue and cell culture
All the first-trimester chorionic villi and placentas were pro-
cessedwithin24hofcollection.Afterthevillihadbeencutinto
small pieces, the tissues were cultured in AmnioMAX-C100
medium (Invitrogen, Carlsbad, Calif., USA), whereas the pla-
centas were washed extensively with phosphate-buffered saline
(PBS).Oncetheamnionhadbeenpeeledoff,eachplacentawas
separated into three parts, namely, the chorionic villus, chori-
onic plate and decidua basalis. To isolate TTCVs, placental
chorionic villi were subsequently minced by using scissors and
re-suspended in MSC basal medium (Lonza, Walkersville,
Md., USA). The FTCVs and TTCVs were maintained sepa-
rately at 37°C in a humidified atmosphere containing 5% CO2
a n dw e r ea l l o w e dt oa t t a c ht ot h e ir culture vessels. After cells
had attached to their vessels, the medium was regularly
changed twice a week. Once the cells had grown to 70%–
80% confluence, they were harvested with trypsin (0.25%)
and 1 mM EDTA (0.02%) in PBS (1:1 v/v) and were subse-
quently plated onto new dishes. After the second passage,
F T C V sw e r ec u l t u r e di nM S Cb a s a lm e d i u m .
The pluripotent human embryonal carcinoma cell line
NTERA-2 clone D1 was purchased from the European Collec-
tion of Cell Cultures (Porton Down, Salisbury, UK). Normal
human dermal fibroblasts (HDFs) were purchased from Lonza.
NTERA-2 and HDFs were cultured in Dulbecco’s modified
Eagle’smedium(DMEM)supplementedwith10%fetalbovine
serum (FBS) and 2 mM glutamine.
Flow cytometric analysis
FTCVs and TTCVs obtained between the third and sixth
passages of culture were characterized by flow cytometric
190 Cell Tissue Res (2012) 348:189–197analysis. Antibodies against human CD29, CD34, CD44,
CD73 and CD105 were purchased from Beckman Coulter
(Brea, Calif., USA) and BD Biosciences Pharmingen (San
Diego, Calif., USA). Briefly, the cells were stained with
primary antibodies and fluorescently labeled secondary anti-
bodies, each for 20 min at 4°C. The cells were then assessed
on an EPICS XL-MCL analyzer (Beckman Coulter). Three
independent experiments were performed in triplicate.
Quantitative analysis by real-time and semi-quantitative
reverse transcription with polymerase chain reaction
TotalRNAwaspreparedbyusingTRIzolReagent(Invitrogen).
Human skeletal muscle total RNA was purchased from
Clontech Laboratories (Mountain View, Calif., USA). An
aliquot of 0.1–2 μg total RNA was reverse-transcribed into
cDNAwithSuperScriptIII ReverseTranscriptase(Invitrogen)
according to the manufacturer’s protocol.
For quantitative real-time reverse transcription (RT) with
polymerase chain reaction (PCR) analysis (qPCR), PCR was
performed by using a Fast Start Universal SYBR Green
Master (ROX) kit (Roche Diagnostics, Mannheim, Germany)
and the Applied Biosystems 7500 Real-Time PCR System
(Applied Biosystems, Foster City, Calif., USA). Relative
expression levels were calculated by using the ΔΔCT method
after normalization to the housekeeping gene GAPDH
(D-glyceraldehyde-3-phosphate dehydrogenase).
Semi-quantitative RT-PCR analysis was performed with
TaKaRa ExTaq (TaKaRa Bio, Shiga, Japan) for 30 cycles,
with each cycle consisting in 94°C for 30 s, 65°C for 30 s and
72°C for 20 s, followed by an additional 10 min incubation at
72°C after completion of the last cycle. The transcript level of
the dystrophin gene was standardized to the ribosomal RNA
18S gene level. The primer sequences used for qPCR and RT-
PCR are listed in SupplementaryTable 1.Foreachexperiment,
at least two independentqPCR and RT-PCR experiments were
performed.
In vitro myogenesis
The method used herein for in vitro myogenesis was mod-
ified as previously described (Kawamichi et al. 2010).
FTCVs obtained between the second and fifth passages of
culture were seeded at a density of 3×10
4 cells/ml in growth
medium (DMEM supplemented with 20% FBS) onto 60-mm
collagen-I-coated cell culture dishes (Asahi Glass, Tokyo,
Japan). At 48 h after being seeded onto the collagen I-coated
dishes,thecellsweretreatedwith5μM5-azacytidine(Sigma-
Aldrich, St. Louis, Mo., USA) for 24 h. Cell culture was then
maintained in differentiation medium (DMEM supple-
mented with 2% horse serum) for 21 days. The differentiation
medium was changed twice a week until the experiment was
terminated.
Dystrophin and myosin heavy chain expression
by immunocytochemistry
The FTCVs obtained before 5-azacytidine treatment and
21 days after treatment were rinsed twice with PBS, fixed with
4% paraformaldehyde in PBS at room temperature for 20 min,
permeabilized with cold 100% methanol on ice for 10 min and
subsequently rinsed with PBS (3×5 min). The cells were
treated with PBS containing 10% horse serum at room tem-
perature for 45 min and were then incubated with rabbit
polyclonal anti-dystrophin antibody (Abcam, Cambridge,
UK) diluted 1:100 with mouse monoclonal anti-sarcomeric
myosin heavy chain protein (MF20; Developmental Studies
Hybridoma Bank, University of Iowa) overnight at 4°C. The
cells were then washed three times with PBS for 10 min and
incubated with secondary antibodies (goat anti-rabbit IgG
[H+L] Alexa Fluor 488 and goat anti-mouse IgG [H+L]
Alexa Fluor 594 conjugate; Molecular Probes, Eugene,
Ore., USA), which were diluted 1:400 with PBS containing
2% bovine serum albumin, for 30 min at room temperature.
After this incubation, the cells were washed with PBS three
times, treated with Hoechst dye (0.1 μg/ml) at room tem-
peraturefor10min,washedwithPBSonce,observedunder
a fluorescence microscope (ECLIPSE TE2000-U; Nikon,
Tokyo, Japan) and then photographed by using an AxioCam
HRC (Carl Zeiss MicroImaging, Tokyo, Japan). All micro-
graphs were taken under identical conditions with the same
exposure time. Three independent experiments were per-
formed in triplicate. The fusion index was determined by
calculating the percentage of nuclei in MF20-positive
(MF20+) myotubes in five randomly encountered fields (a
magnification of ×200 per field) per well in triplicate wells.
Pluripotent marker expression by immunocytochemistry
TheFTCVsobtainedbefore5-azacytidinetreatmentand1day
after treatment were rinsed twice with PBS, fixed with 4%
paraformaldehyde in PBS atroomtemperaturefor 20 min and
permeabilized with 0.1% Triton X-100 in PBS for 10 min and
subsequently rinsed with PBS (3×5 min). The cells were
treated with PBS containing 10% goat serum at room temper-
ature for 45 min and were then incubated with primary anti-
bodies (rabbit monoclonal anti-Nanog, Oct4, Sox2 antibody;
Cell Signaling Technology, Danvers, Mass., USA) diluted
1:400 with 10% goat serum in PBS overnight at 4°C. Then,
the cells were washed three times with PBS for 10 min and
incubated with secondary antibodies (goat anti-rabbit IgG
[H+L] Alexa Fluor 488 and goat anti-mouse IgG [H+L]
Alexa Fluor 594 conjugate; Molecular Probes), which were
diluted1:400 with PBScontaining2%bovineserumalbumin,
for30minatroomtemperature.Afterthisincubation,thecells
were washed with PBS three times, treated with Hoechst dye
Cell Tissue Res (2012) 348:189–197 191at room temperature for 10 min, washed with PBS once and
then observed under a fluorescence microscope.
Western blotting
The FTCVs obtained before 5-azacytidine treatment and
21 days after treatment on 60-mm collagen-I-coated dishes
were scraped in 1 ml homogenizing buffer consisting in
0.02 mol/l NaOH, 1% sodium dodecyl sulfate (SDS, Sigma-
Aldrich), 5 mM O,O′-Bis [2-aminoethyl] ethyleneglycol-N,
N, N′,N ′-tetraacetic acid (Dojindo Molecular Technologies,
Kumamoto, Japan) and Complete Mini (Roche Diagnostics),
on ice and the cells were collected. Homogenates were col-
lected in separate microcentrifuge tubes and centrifuged at
15,000g for 30 min at 4°C. Equal amounts of protein
(10 μg) were loaded onto SDS-polyacrylamide gels and blot-
tedontoImmobilon-Pmembranes(Millipore,Bedford,Mass.,
USA) by using a semi-dry transfer system (Atto, Tokyo,
Japan). The blots were incubated with primary antibodies
against dystrophin (NCL-DYS2 [1:200] and NCL-DYS3
[1:50; Novocastra Laboratories, Newcastle upon Tyne, UK])
for 3 h at room temperature and were subsequently washed
three times with blocking buffer. The blots were then incubat-
ed with a peroxidase-conjugated goat anti-mouse IgG (H+L)
secondary antibody (0.05 μl/ml; Jackson ImmunoResearch
Laboratories, West Grove, Pa., USA; directed against the
primary antibody) for 2 h at room temperature. The mem-
branes were subsequently treated with an enzyme chemilumi-
nescence assay (ECL plus Western Blotting Detection
System; GE Healthcare, Buckinghamshire, UK) and the reac-
tions were visualized by exposing the membranes to an X-ray
film (Hyperfilm ECL; GE Healthcare) overnight.
Results
Expression of mesenchymal stem cell markers
in undifferentiated FTCVs and TTCVs
We successfully cultureda largenumberofprimary cells from
FTCVs and TTCVs and found that these cells showed a
fibroblast-like morphology at the second passage of culture
(Fig. 1a, b). After isolation of the cells, we immunocytochem-
ically evaluated the expression of the surface markers present
on the uninduced FTCVs and TTCVs from three individuals
by flow cytometry (Table 1). Both FTCVs and TTCVs were
positive for MSC markers CD29, CD44, CD73 and CD105
but were negative for the CD34 hematopoietic marker, indi-
cating that both the FTCV- and TTCV-cultured populations
 Fig. 1 Phase contrast microscopic images of undifferentiated first-
trimester chorionic-villi-derived cells (FTCVs; a) and third-trimester
placental chorionic-villi-derived cells (TTCVs; b). Bar 50 μm. c
Quantitative real-time reverse transcription with polymerase chain
reaction (qPCR) analysis for Nanog, Sox2 and Oct4 mRNA expression
in FTCVs at the 9th (FTCV-9th), 10th (FTCV-10th) and 11th (FTCV-
11th) weeks of gestation, TTCVs, normal human dermal fibroblasts
(HDFs) and a pluripotent human embryonic carcinoma cell line
(NTERA-2). The value for NTERA-2 was set to 1 in each experiment.
Each value (n04) represents the mean±SD
192 Cell Tissue Res (2012) 348:189–197were depleted of hematopoietic cells. Furthermore, we found
that the average level of MSC marker expression on the
FTCVs was higher than that on the TTCVs but this difference
was not statistically significant.
Expression of pluripotent stem cell markers by FTCVs
We also analyzed the gene expression of pluripotent stem cell
markers in uninduced FTCVs and TTCVs obtained between
the 3rd and 6th passages of culture by qPCR analysis. FTCVs
c o l l e c t e dd u r i n gt h e9 t hw e e ko fg e s t a t i o n( F T C V - 9 t h )
expressed both Nanog and Sox2 mRNA but not Oct4 mRNA
(Fig. 1c). In contrast, FTCVs collected during later weeks of
gestation (FTCV-10th, FTCV-11th) and TTCVs exhibited no
detectable expression of these pluripotent stem cell markers.
Moreover,immunocytochemicalanalysisrevealedthepresence
of the Nanog protein in uninduced FTCV-9th cells (Fig. 2a).
Myogenic differentiation
To evaluate their myogenic potential, the differentiation of the
FTCVs into a myogenic lineage was induced by incubation
with 5-azacytidine in DMEM with 20% FBS for 24 h, after
which they were cultured in DMEM supplemented with 2%
horse serum for 21 days. We found that FTCVexpression of
both Nanog and Sox2 mRNA decreased markedly after 1 day
of myogenic induction (Fig. 2g); indeed, the Nanog protein
was also down-regulated after myogenic induction (Fig. 2d).
During myogenic induction, the morphology of the FTCV
population changed to multinucleated myotubes (Fig. 3). We
evaluated the expression of the myogenic markers MyoD,
myogenin, desmin and dystrophin in the FTCVs by qPCR
analysis. These experiments revealed that myogenic differen-
tiation of the FTCVs induced both MyoD and myogenin
mRNAexpressionbyday3,althoughthisexpressiondecreased
again by day 7. Moreover, FTCVexpression of desmin mRNA
Table 1 Flow cytometric analysis of primary cultures without induc-
tive stimuli. Percentages of TTCVs and FTCVs immunostained for
CD29, CD44, CD73, CD105 and CD34 (mean±SD, n03; FITC fluo-











TTCVs 96.9±2.2 94.7±4.86 87.3±10.8 91.5±9.25 0.27
FTCVs 98.8±1.0 97.2±1.89 93.6±4.23 98.1±2.03 0.27
Fig. 2 Immunocytochemistry
of the Nanog protein. a Nanog
(day 0). b Hoechst dye (day 0).
c Merged image of a, b (day 0).
d Nanog (day 1). e Hoechst dye
(day 1). f Merged image of d, e
(day 1). Bar 50 μm. g qPCR
analysis of Nanog and Sox2
expression in FTCV-9th cells.
Time course of Nanog and Sox2
mRNA expression at the indi-
cated day after treatment with
5-azacytidine. The value
obtained before treatment with
5-azacytidine was set to 1 in
each experiment
Cell Tissue Res (2012) 348:189–197 193was relatively high on day 1 of myogenic differentiation and
subsequentlydecreasedtoa moderate level (Fig. 4).Inaddition,
RT-PCR analysis clearly showed that dystrophin mRNA
expression was increased from day 14 (Fig. 5a), as confirmed
byqPCRanalysis(Fig.5b).ImmunocytochemistryandWestern
blot analysis also confirmed that the dystrophin protein was
detected in the FTCVs at day 21 (Fig. 6a, d). To evaluate the
efficiency of myotube formation, FTCVs and TTCVs were
fixed at day 0 and day 21 after plating and stained as described
in Materials and methods with an antibody to the myosin heavy
chain protein (MF20) in order to determine the fusion index.
The results revealed that FTCV-9th cells with a fusion index of
57.3±11.1% had significantly higher myogenicity than FTCV-
11th cells (20.9±6.4%) and TTCVs (9.9±1.4%) at day 21
(Fig. 7).
In vitro differentiation of multiple lineages
qPCR analysis revealedthat FTCVs treatedwith 5-azacytidine
and maintained in myogenic culture conditions also expressed
RUNX2, Sox9, PPARγ, nestin, ACTA2 and GATA4, which are
markers of the osteoblast, chondrocyte, adipocyte, neural,
smooth muscle and cardiac lineages, respectively (Fig. 8).
Furthermore, the relative levels of expression of these non-
myogenic markers were lower than the expression levels of
myogenic markers such as desmin and dystrophin.
Discussion
In this study, we have investigated the myogenic potential of
FTCVs as a cell source for muscular dystrophy cell therapy.
To our knowledge, no previous studies have examined the
effect of combining 5-azacytidine treatment with culture in
myogenic differentiation media on the expression of dystro-
phin in FTCVs. Recently, stem cells have been investigated
intensively for their potential use in various therapeutic regi-
mens,includingtissueengineeringandcelltherapy.Stemcells
Fig. 3 Phase contrast microscopic images of the FTCVs and TTCVs
after treatment with 5-azacytidine. a FTCVs (day 7). b TTCVs (day 7),
c FTCVs (day 21), d TTCVs (day 21). Bar 50 μm
Fig. 4 qPCR analysis of skeletal muscle markers in the FTCVs. Time
course of MyoD (a), myogenin (b) and desmin (c) mRNA expression at
the indicated day after treatment with 5-azacytidine. MyoD mRNAwas
detectable after day 3. Myogenin mRNAwas undetectable at day 0. The
earliest detectable value was set to 1 in each experiment
194 Cell Tissue Res (2012) 348:189–197can be loosely classified into three groups: embryonic stem
(ES) cells, fetal stem cells (i.e., first-trimester chorionic villi
and placenta) and adult stem cells. In particular, FTCVs
possess a number of advantages that contribute to their poten-
tial therapeutic use. First, FTCVs might have a higher myo-
genic potential for differentiation than cells taken from other
tissues because they are derived from the earliest fetal
cell population. Second, the ability to isolate pluripo-
tent autogenic progenitor cells such as FTCVs during
gestation might be advantageous for the timely treat-
ment of genetic diseases in newborns. Third, fetal cells
do not form teratomas when injected into adults and are
less immunogenic than other cell population, making
them particularly suitable for transplantation (In’tA n k e r
et al. 2003; De Coppi et al. 2007). Fourth, the use of
FTCVs for treatment avoids the ethical issues associat-
ed with ES cells (Weiss and Troyer 2006). Finally,
FTCVs are obtained within the process of prenatal
diagnosis and can be taken without an additional invasive
procedure.
Our present results suggest that FTCVs express Nanog and
Sox2 mRNA, the proteins of which have been previously
identified as crucial factors for maintaining stem cell charac-
teristics in human ES cells (Hoffman and Carpenter 2005;
Kazuki et al. 2010). The expression level of Nanog mRNA in
the FTCVs collected during the 9th week of gestation is not
significantly different from that of NTERA-2 cells, which
express pluripotent stem cell markers (Pal and Ravindran
2006; Fig. 1c). Our investigation of pluripotent stem cell
marker expression in the FTCVs collected between the 9th
and 11th weeks of gestation has revealed that both Nanog and
Fig. 5 Expression of dystrophin mRNA in the FTCVs during myo-
genic induction. a RT-PCR analysis. Time course of dystrophin and
ribosomal RNA 18S mRNA expression at the indicated day after
treatment with 5-azacytidine (N negative control lanes without reverse
transcriptase, P RNAs from human skeletal muscle as positive control).
b qPCR analysis. Time course of dystrophin mRNA expression at the
indicated day after treatment with 5-azacytidine. The value obtained
before treatment with 5-azacytidine was set to 1. Each value (n03)
represents the mean±SD
Fig. 6 Immunocytochemistry of dystrophin (green) and myosin heavy
chain (red) proteins in FTCVs at 21 days after 5-azacytidine treatment.
The nuclei were counterstained with Hoechst dye (blue). a Dystrophin. b
Myosin heavy chain (MF20). c Merged image of a, b. Bar 50 μm. d
Western blot of dystrophin (using C-terminus [NCL-DYS2] and N-
terminus [NCL-DYS3] antibodies) in the FTCV lysate before 5-
azacytidine treatment (day 0) and at day 21 after 5-azacytidine treatment
Fig. 7 Quantification of MF20-positive (MF20+) cells in FTCV-9th
cells, FTCV-11th cells and TTCVs during in vitro differentiation.
Fusion index was determined by calculating the percentage of nuclei
among MF20+ cells, as described. Each data point (n03) is presented
as the mean±SD. Quantification of MF20+ cells in each population
was compared by using the Student’s t-test (*, P<0.05)
Cell Tissue Res (2012) 348:189–197 195Sox2 mRNA are expressed in the cells collected during the 9th
week. Immunocytochemistry hasrevealedthatNanog-protein-
positive cells constitute only a small population of the FTCV-
9th cells (Fig. 2a). Because FTCVs exhibit heterogeneity,
which suggests the presence of other stem-cell-like cells,
additional studies are required to assess further the expression
pattern ofstem cell markers. However, these dataconfirm that
the FTCV-9th cells contain a subpopulation of uncommitted
progenitorsthatexpressNanogand Sox2mRNA and thatthey
are likely to be distinct from the committed MSC population.
We have also confirmed that FTCVs expressed MSC markers
at a high level (Table 1). Although the FTCVs from the 10th
and 11th weeks do not express Nanog and Sox2 mRNA, they
do express myogenic markers, including dystrophin, after
myogenic induction. These data indicate that FTCVs possibly
down-regulate the expression of Nanog and Sox2 mRNA
between the 9th and 10th weeks of gestation (Fig. 1c). On
thebasisofthesefindings,weconcludethatthecharacteristics
of our FTCV-9th population require further detailed analysis.
Furthermore, our results indicate that FTCVs can be efficient-
lydirectedtodifferentiateinvitrointoskeletalmusclecellsthat
express dystrophin (Fig. 6). Dystrophin is a mature skeletal
muscle protein produced during cell fusion (Edmondson and
Olson 1993).
Under the myogenic differentiation conditions used in
this study, FTCVs exhibit a greater increase in the expres-
sion of myogenic markers than any other lineage markers
(Fig. 8). Indeed, MSCs derived from TTCVs can be induced
to differentiate into skeletal muscle by treatment with 5-
azacytidine in DMEM with 20% FBS and subsequent cul-
ture in 2% horse serum. Initially, we optimized the cell
concentration used in the present study from this previously
reported culture method (Kawamichi et al. 2010) but our
modified method led to the further formation of myotubes in
the FTCVs. Although such myogenic induction was proba-
bly caused by transient and random gene modifications
attributable to treatment with the DNA demethylation agent
5-azacytidine, our myogenic culture conditions might have
increased the effectiveness of myogenesis in the FTCVs.
Since DMD-derived FTCVs are regularly obtained during
early pregnancy for prenatal diagnosis purposes, they are a
stable source of cells with pluripotent and myogenic differen-
tiation potential. Furthermore, the DMD-derived FTCVs can
be easily cultured in vitro. These cells can be manipulated by
using gene-targeting protocols that involve a mini-dystrophin
gene(Tangetal.2010),othergenesusingviralvectors(Odom
et al. 2008), or antisense morpholinos (Saito et al. 2010).
Alternatively, they can be treated with pharmacological
agents, such as aminoglycoside (Barton-Davis et al. 1999;
Malik et al. 2010)o rn e g a m y c i n( A r a k a w ae ta l .2003;
Allamand et al. 2008), which target the nonsense mutation in
the dystrophin gene of about 15% of DMD patients. These
particular properties of the FTCVs might enable effective
DMDtreatmentbyallowingtheuseofapatient’sow nF TC Vs
for self-transplantation with one of the above-mentioned gene
therapies. Myogenic differentiation of reimplanted FTCVs in
situcouldtheoreticallyrepopulateandrepairthedysfunctional
skeletal muscles in DMD. Furthermore, a combination of
targeted gene manipulation and pharmacological treatments
that enable stem cells to grow and differentiate indefinitely
could further extend the possibletherapeuticpotential ofthese
cells. Moreover, such manipulations of stem cells offer the
potential of developing protocols to cure genetic defects and
to assess in great detail the functionality and safety of thera-
peutic protocols in vitro. Indeed, patient-derived FTCVs
might be suitable for self-transplantation with nonimmunoge-
nicity or low immunogenicity and non-tumorigenicity. Even
FTCVs with a different genetic background might represent a
novel cell source for transplantation because of their low
immunogenicity and lack of need for immunosuppressive
agents.
The expression of markers for MSCs, pluripotent
stem cells and myogenic cells in the FTCV population
opens up new possibilities in cell therapy for DMD
patients and individuals with other neuromuscular diseases.
Further in vivo studies,which are currently under way, will be
essential for identifying the factors that determine the condi-
tions for definitive myogenic differentiation, survival and
dissemination and the potential clinical effects of these cells
in animal models.
In summary, FTCVs that have been previously obtained
for prenatal diagnosis express markers of MSCs and plurip-
otent stem cells and undergo myogenesis efficiently in vitro.
The accessibility of FTCVs and the minimal ethical issues
involved with obtaining these cells make them promising
therapeutic candidates for patients suffering from DMD.
Fig. 8 qPCR analysis of multiple tissue markers in FTCVs. Time
course of RUNX2, Sox9, PPARγ, nestin, ACTA2 and GATA4 and
skeletal muscle marker (desmin and dystrophin) mRNA expression at
the indicated day after treatment with 5-azacytidine. The value
obtained before treatment with 5-azacytidine was set to 1 in each
experiment
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